Cover Image
市場調查報告書

ADC Therapeutics Sarl 產品平台分析

ADC Therapeutics Sarl - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 318950
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
ADC Therapeutics Sarl 產品平台分析 ADC Therapeutics Sarl - Product Pipeline Review - 2015
出版日期: 2015年02月24日 內容資訊: 英文 26 Pages
簡介

ADC Therapeutics Sarl 是在瑞士設有總公司的藥物研發企業。致力於開發以乳癌、前列腺癌、腎臟癌、血癌等主要癌症為標的ADC。正藉由與Spirogen Limited、Cancer Research Technology的策略性合作進行研究開發。

本報告提供ADC Therapeutics Sarl 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

ADC Therapeutics Sarl 基本資料

  • ADC Therapeutics Sarl 概要
  • 主要資訊
  • 企業資料

ADC Therapeutics Sarl :R&D概要

  • 主要的治療範圍

ADC Therapeutics Sarl :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

ADC Therapeutics Sarl :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

ADC Therapeutics Sarl :藥物簡介

  • ADCT-401
  • Monoclonal Antibody Conjugates for Prostate Cancer
  • Monoclonal Antibody Conjugates for Solid Tumor and Blood Cancer
  • VM-101
  • Monoclonal Antibody Conjugates for Cancer

ADC Therapeutics Sarl :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

ADC Therapeutics Sarl :最新的開發平台資訊

ADC Therapeutics Sarl :開發暫停中的計劃

ADC Therapeutics Sarl :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06797CDB

Summary

Global Markets Direct's, 'ADC Therapeutics Sarl - Product Pipeline Review - 2015', provides an overview of the ADC Therapeutics Sarl's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ADC Therapeutics Sarl's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ADC Therapeutics Sarl including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ADC Therapeutics Sarl's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ADC Therapeutics Sarl's pipeline products

Reasons to buy

  • Evaluate ADC Therapeutics Sarl's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ADC Therapeutics Sarl in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ADC Therapeutics Sarl's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ADC Therapeutics Sarl and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ADC Therapeutics Sarl
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ADC Therapeutics Sarl and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ADC Therapeutics Sarl Snapshot
    • ADC Therapeutics Sarl Overview
    • Key Information
    • Key Facts
  • ADC Therapeutics Sarl - Research and Development Overview
    • Key Therapeutic Areas
  • ADC Therapeutics Sarl - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • ADC Therapeutics Sarl - Pipeline Products Glance
    • ADC Therapeutics Sarl - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ADC Therapeutics Sarl - Drug Profiles
    • ADCT-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADCT-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Solid Tumor and Blood Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ADC Therapeutics Sarl - Pipeline Analysis
    • ADC Therapeutics Sarl - Pipeline Products by Target
    • ADC Therapeutics Sarl - Pipeline Products by Molecule Type
    • ADC Therapeutics Sarl - Pipeline Products by Mechanism of Action
    • ADC Therapeutics Sarl - Recent Pipeline Updates
  • ADC Therapeutics Sarl - Dormant Projects
  • ADC Therapeutics Sarl - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ADC Therapeutics Sarl, Key Information
  • ADC Therapeutics Sarl, Key Facts
  • ADC Therapeutics Sarl - Pipeline by Indication, 2015
  • ADC Therapeutics Sarl - Pipeline by Stage of Development, 2015
  • ADC Therapeutics Sarl - Monotherapy Products in Pipeline, 2015
  • ADC Therapeutics Sarl - Partnered Products in Pipeline, 2015
  • ADC Therapeutics Sarl - Partnered Products/ Combination Treatment Modalities, 2015
  • ADC Therapeutics Sarl - Preclinical, 2015
  • ADC Therapeutics Sarl - Discovery, 2015
  • ADC Therapeutics Sarl - Pipeline by Target, 2015
  • ADC Therapeutics Sarl - Pipeline by Molecule Type, 2015
  • ADC Therapeutics Sarl - Pipeline Products by Mechanism of Action, 2015
  • ADC Therapeutics Sarl - Recent Pipeline Updates, 2015
  • ADC Therapeutics Sarl - Dormant Developmental Projects,2015

List of Figures

  • ADC Therapeutics Sarl - Pipeline by Top 10 Indication, 2015
  • ADC Therapeutics Sarl - Pipeline by Stage of Development, 2015
  • ADC Therapeutics Sarl - Monotherapy Products in Pipeline, 2015
  • ADC Therapeutics Sarl - Pipeline by Top 10 Molecule Type, 2015
Back to Top